Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf133 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Chenjing Zhu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cance…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, DNA-Binding Proteins, Chemoradiotherapy, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Medical Research Project of Jiangsu Provincial Health Commission, Jieping Medical Foundation Clinical Research Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and purpose Definitive chemoradiotherapy (dCRT) is the standard treatment for locally advanced cervical cancer (LACC), yet patients experience considerable variability in disease-free survival (DFS). This study aimed to identify molecular biomarkers associated with response to dCRT in cervical cancer. Materials and methods: We retrospectively analyzed targeted next-generation sequencing data from tumor biopsy samples of 31 patients diagnosed with FIGO stage IIB–IVA LACC. Genetic alterations in cancer-related genes and pathways were assessed to determine associations with DFS. Immune cell infiltration and gene expression were analyzed using data from The Cancer Genome Atlas.
Results
Genetic alterations were frequently detected in PIK3CA (45.2%), EP300 (25.8%), RB1 (19.4%), FBXW7 (19.4%), and FAT1 (16.1%). Multivariate analysis identified mutations in ARID1A and B2M as independent predictors of poor DFS. Alterations in the antigen processing and presentation pathway were also associated with reduced survival rates. Patients with ARID1A and B2M mutations exhibited decreased immune cell infiltration and impaired antigen presentation, indicating a compromised immune response.
Conclusion
ARID1A and B2M mutations may serve as potential biomarkers for predicting treatment outcomes in cervical cancer patients undergoing dCRT. Testing for these mutations could help identify patients at higher risk of poor outcomes, guiding personalized treatment strategies to improve survival rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, People's Republic of China.
- Department of Gynecology, Women's Hospital of Nanjing Medical University & Nanjing Women and Children's Healthcare Hospital, Nanjing 210004, People's Republic of China.
- Nanjing Geneseeq Technology Inc., Nanjing 210000, People's Republic of China.
ORCID-Profile: Hanzi Xu
Förderung
- Key Medical Research Project of Jiangsu Provincial Health Commission
- Jieping Medical Foundation Clinical Research Fund
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Zhu, C., Gong, Z., Yin, P., Huang, J., He, D., Zhu, B., Wu, Y., Wang, H., Zhang, Y., Jing, Q., Yin, J. C., Li, Y., Liu, J., Hu, H., Xiao, S., Sun, Z., & Xu, H. (2025). Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyaf133
Vancouver
Zhu C, Gong Z, Yin P, Huang J, He D, Zhu B, et al. Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyaf133
BibTeX
@article{Zhu2025,
author = {Zhu, Chenjing and Gong, Zhen and Yin, Ping and Huang, Jian and He, Dan and Zhu, Biqing and Wu, Yaqin and Wang, Hairong and Zhang, Yaru and Jing, Qifan and Yin, Jiani C and Li, Yue and Liu, Jianyao and Hu, Huanhuan and Xiao, Shuyue and Sun, Zhihua and Xu, Hanzi},
title = {Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf133}
}
EUVIMED